Seeking Alpha

Seeking Alpha Portfolio App for iPad

LATEST ARTICLES

ARTICLES | NEWS | TRANSCRIPTS

Trius Patent Intrigues Investors, And Perhaps Cubist Pharmaceuticals
PropThink • CBST, TSRX • Thu, May 16, 09:57 ET
Genomic Health's New Prostate Test May Extend The Stock's Upward Climb
Amy Baldwin • MYGN, GHDX • Wed, May 15, 18:27 ET
Trius Therapeutics: New, Positive Dimension For Investment Outlook
Smith On Stocks • CBST, TEVA, TSRX • Mon, May 13, 18:27 ET
Enzo Biochem's Intellectual Property Protection To Attract Investor Attention In 2013
Chemistfrog • AFFX, GPRO, LIFE • Mon, May 13, 08:04 ET
Psychemedics Corp: Splitting Hairs For Profit
Bram de Haas • PMD • Sun, May 12, 03:17 ET
Undue Pressure On Trius Creates An Entrance Point
PropThink • TSRX • Thu, May 2, 11:08 ET
China Cord Blood: Evaluating Buyout Potential
Richard Pearson • CO • Wed, May 1, 10:25 ET
Could Enzo Biochem's Intellectual Property Lawsuits Be Worth Billions?
Glen S. Woods • ABT, VRNG, ACTG • Sun, Apr 28, 19:00 ET
TearLab: Watch For A Sharp Drop On Equity Offering
Richard Pearson • TEAR • Wed, Apr 24, 09:30 ET
Why Bio-Reference Laboratories Is A Dangerous Investment
StockBaller • BRLI • Thu, Apr 11, 19:32 ET
Trius: Clinical Trials Show Important Differentiation Of Tedizolid From Zyvox
Smith On Stocks • TSRX • Tue, Apr 9, 04:54 ET
Alliance Healthcare Services: Worth At Least $10.60, Probably More
Intangible Valuation • RDNT, AIQ • Mon, Apr 1, 12:24 ET
5 Reasons Why Bio-Reference Laboratories Is A Solid Stock
Jae Jun • BRLI • Mon, Apr 1, 10:37 ET
If Quest Returns To Its Core Strengths, It Can Deliver Big Returns For Shareholders
Paul Nouri • LH, TMO, HOLX • Thu, Mar 21, 16:46 ET
Trius Therapeutics Is A Strong Investment Short And Long Term
John Eastman • CBST, TSRX • Thu, Mar 21, 16:42 ET
Enzo Investors Have To Be In It For The Long Haul
Paul Nouri • LIFE, ENZ • Wed, Mar 20, 16:52 ET
Trius: Topline Data From Second Phase III Trial Of Tedizolid Is Imminent
Smith On Stocks • CBST, DRTX, MDCO • Mon, Mar 18, 08:54 ET
Trius: Phase III Data For Tedizolid Imminent
PropThink • TSRX • Thu, Mar 14, 14:28 ET
Can TearLab Stay On A Tear?
Stephen Simpson • AGN, COO, NVS • Thu, Mar 14, 11:15 ET
Cannabis Science Masters The Art Of Shareholder Dilution
Alan Brochstein • CBIS.OB • Mon, Mar 11, 10:42 ET
Trius: Establishing A Compelling Case For Tedizolid
David Sobek • TSRX • Tue, Mar 5, 12:27 ET
Trius Therapeutics: New MRSA Treatment Could Bring Billions In Revenues
Scott Matusow • AMRN, ARNA, PFE • Tue, Mar 5, 09:28 ET
Bio-Reference: Claims Don't Match The Evidence
The Street Sweeper • BRLI • Mon, Mar 4, 14:22 ET
NeoGenomics: Poised To Grow Further In 2013 And Beyond
Grant Zeng • NEO • Thu, Feb 28, 13:52 ET
How They Found The Next Vringo
Greg Miller • PRKR, VRNG, SPEX • Thu, Feb 28, 11:39 ET
Quest Diagnostics Tests Positive For Value, Negative For Growth
MagicDiligence • DGX • Tue, Feb 26, 01:40 ET
3 Small Cap Biotech Plays Potentially Facing Cash-Flow Issues
Matt Schilling • BGMD, NEO, RGDX • Mon, Feb 18, 07:30 ET
Radnet: Growing Business Conceals Cash Generation, But Is It Enough To Offset The Massive Debt?
Intangible Valuation • AIQ, RDNT • Tue, Feb 12, 15:06 ET
Time To Dump Diluted Shares Of Trius - Or Double Down?
Rex Graham • TSRX • Tue, Feb 12, 05:10 ET
Response Genetics' Competitors: Who To Watch, Who To Worry About
Bay Area Biotech • ACUR, AKRX, BGMD • Fri, Feb 8, 12:01 ET
Trius Therapeutics: Takeover Candidate In 2013
Bob's Stocks • CBST, TSRX • Mon, Feb 4, 05:46 ET
Alliance Healthcare: Valuing Trouble
iEconomists • AIQ • Fri, Feb 1, 16:07 ET
Why The Trius Offering Is A Positive Move
John Eastman • TSRX • Wed, Jan 23, 10:54 ET
Trius: Why Last Friday's Equity Offering Is Good For The Stock
Smith On Stocks • TSRX • Mon, Jan 21, 09:00 ET
The Momentum Of Trius Therapeutics
Steven Barnes • TSRX • Fri, Jan 18, 12:44 ET
Trius: In An About Face, Congress Is Helping Biotech Companies That Are Developing Antibiotics
Smith On Stocks • TSRX • Mon, Jan 14, 11:58 ET
The Impact Of Off-Label Use Of Zyvox And Its Import For Trius And Tedizolid
David Sobek • TSRX • Thu, Jan 10, 05:35 ET
Trius Quickens Pace Towards Commercialization With FDA Designation For Tedizolid Phosphate
John Eastman • TSRX • Mon, Jan 7, 13:36 ET
An Undervalued Healthcare High Dividend Stock With Good Growth For 2013
Double Dividend Stocks • PMD • Sat, Jan 5, 14:01 ET
End Of The Year Shopping Spree Should Have Trius On The List
Kyle Rankin • TSRX • Fri, Dec 28, 2012, 10:14 ET
BG Medicine: This Forgotten IPO Is A Hidden Gem
Robert Fabian • BGMD • Thu, Dec 27, 2012, 10:48 ET
Resistance (To Resistance) Is Futile: The Growing Opportunity For Trius And Tedizolid
David Sobek • TSRX • Thu, Dec 20, 2012, 17:08 ET
Bear Thesis On Trius Therapeutics Seems Flawed
PropThink • OPTR, CBST, PFE • Tue, Dec 18, 2012, 14:00 ET
Trius: The Winner In The War Against MRSA
Suresh Gupta • BAYZF.PK, PFE, TSRX • Tue, Dec 11, 2012, 12:53 ET
Trius Therapeutics: A Long, Stable, And Steady Play
John Eastman • TSRX • Thu, Dec 6, 2012, 03:46 ET
Trius Therapeutics: Tedizolid's Potential Commercial Paths
David Sobek • TSRX • Wed, Dec 5, 2012, 08:24 ET
How Trius Will Undercut Pfizer's Zyvox In The Battle Against MRSA
EricFinance • BAYRY.PK, PFE, TSRX • Sun, Dec 2, 2012, 05:59 ET
Update On Emerging Biomarker Diagnostics: BG Medicine, Response Genetics, Vermillion
Rod Raynovich • BGMD, VRML, RGDX • Thu, Nov 15, 2012, 14:11 ET
Clinical Milestones Aside, The Case For Trius Has Other Angles
Richard Richter • BAYRY.PK, PFE, TEVA • Wed, Nov 14, 2012, 12:14 ET
Consider Ironwood Pharmaceuticals Amidst Strong Insider Support
Kevin Quon • AZN, BMR, IRWD • Tue, Nov 13, 2012, 07:46 ET

First Page
Previous Page
1 - 50 of 189
Next Page
Last Page